Project Grant R43DK142274

Award Date 7/15/25
Completion Date 6/30/26
Dollars Obligated $226K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $704,672 to Flowpoint Medical Inc. to develop an implantable self-sealing needle guide system to improve vascular access and safety for hemodialysis patients. The award will fund the refinement of the device's manufacturability and operational parameters, as well as a large animal...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on developing novel bioengineered regenerative medicine solutions based on vasculogenic regenerative medicine technology. The $543,826 award, granted on December 10, 2024, aims to investigate the mechanisms underlying in vivo vasculogenic reprogramming, specifically examining...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $499,890 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Pavaj Vascular Corporation to develop a novel therapy to prevent arteriovenous fistula (AVF) venous stenosis, a common complication in end-stage kidney disease patients requiring hemodialysis. The funding will support two main goals: 1) evaluating the stability and biocompatibility of a nanoparticle-based...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $1,583,229 Project Grant to Boston Medical Center Corporation to evaluate the use of intravascular ultrasound (IVUS) imaging for diagnosing and managing arteriovenous (AV) access dysfunction in end-stage kidney disease patients on hemodialysis. The 5-year grant project will compare the accuracy of IVUS versus...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $324,678 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Lumina Medical LLC, a for-profit limited liability company located in Culver City, California. The grant supports the development of a motorized, girth-adjustable anal dilator device designed to improve patient adherence to anal dilation treatments for conditions such as anismus and anal...
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,712,226 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Orphagen Pharmaceuticals, Inc. The grant supports the development of a novel, first-in-class class of small molecule antagonists that inhibit the gut migration of activated T cells, which is a promising therapeutic approach for treating inflammatory bowel disease (IBD). Preliminary data...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $708,138 to support the development of a biomechanocompatible small molecule-releasing scaffold for bladder augmentation. The goal is to create an alternative to conventional surgical approaches that use detubularized bowel tissue, which can have significant complications. The...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $298,371 to Anova Biomedical, Inc. to develop a new class of biodegradable and elastic vascular grafts for hemodialysis. The funding will be used to refine manufacturing techniques for these grafts, which are designed to closely resemble the mechanical properties of native vasculature and slowly remodel into...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $436,277 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Delaware. The grant titled "NEPHROGENESIS ON A CHIP: AN SIMPLE MODULAR PLATFORM TO SPATIALLY PATTERN EXTRACELLULAR MATRIX, STROMAL CELLS, AND SOLUBLE FACTORS" aims to develop an easy-to-use 3D in vitro model of the developing nephron that allows spatial patterning...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $226,192 to Endonavis LLC, a small disadvantaged business located in Louisville, Kentucky. The grant supports the development of a novel over-the-scope platform for controlling variceal bleeding, a major complication of cirrhosis. The project aims to design a therapeutic balloon/catheter system with endoscopic visualization capabilities to improve the safety and effectiveness of treating upper gastrointestinal variceal hemorrhage, which can be life-threatening. The award period runs from July 15, 2025 through June 30, 2026, with the goal of producing a functional bleeding control system ready for further verification and validation testing prior to commercialization.

Generated 8/5/25, 3:43 AM